| 2026-08-04 | Press release | PDF Version |
| 2026-08-04 | Press release | CUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS |
| 2026-07-28 | Press release | CUMBERLAND PHARMACEUTICALS TO ANNOUNCE COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS |
| 2026-07-13 | Press release | PDF Version |
| 2026-07-13 | Press release | CUMBERLAND PHARMACEUTICALS ANNOUNCES SPECIAL DIVIDEND OF $1.50 PER SHARE |
| 2026-07-13 | Press release | /C O R R E C T I O N -- Cumberland Pharmaceuticals Inc./ |
| 2026-07-01 | Press release | Cumberland Pharmaceuticals Closes Strategic Transaction with Apotex |
| 2026-06-26 | Press release | Cumberland Pharmaceuticals Shares Updated FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Confer |
| 2026-06-02 | Press release | Cumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer Metastasis |
| 2026-05-28 | Press release | CUMBERLAND PHARMACEUTICALS ANNOUNCES LAUNCH OF VIBATIV® IN CHINA |
| 2026-05-05 | Press release | CUMBERLAND PHARMACEUTICALS REPORTS Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE |
| 2026-04-28 | Press release | CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE |
| 2026-04-23 | Press release | Cumberland Pharmaceuticals Announces Strategic Transaction to Integrate Commercial Business with Apotex |
| 2026-04-16 | Press release | CUMBERLAND PHARMACEUTICALS ANNOUNCES EXPANDED INDICATION FOR CALDOLOR® (IBUPROFEN) INJECTION AND LAUNCH OF NEW BRAND WE |
| 2026-03-17 | Press release | Cumberland Pharmaceuticals Launches New Sancuso® Website Featuring Educational Resources for Chemotherapy-Induced Nausea |
| 2026-03-03 | Press release | PDF Version |
| 2026-03-03 | Press release | Cumberland Pharmaceuticals Reports 31% Fourth Quarter 2025 Revenue Growth |
| 2026-02-25 | Press release | CUMBERLAND PHARMACEUTICALS LAUNCHES U.S. PROMOTION OF TALICIA® |
| 2026-02-24 | Press release | CUMBERLAND PHARMACEUTICALS TO ANNOUNCE 2025 ANNUAL FINANCIAL RESULTS & COMPANY UPDATE |
| 2026-02-04 | Press release | Cumberland Pharmaceuticals Receives FDA Fast Track Designation for its Ifetroban Duchenne Muscular Dystrophy Program |
| 2025-03-04 | Press release | Cumberland Pharmaceuticals Reports 11.6% Fourth Quarter 2024 Revenue Growth |
| 2024-11-07 | Press release | Cumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update |
| 2024-08-06 | Press release | Cumberland Pharmaceuticals Reports 16% Sequential Revenue Growth in Second Quarter 2024 |
| 2024-05-07 | Press release | Cumberland Pharmaceuticals Reports First Quarter 2024 Financial Results & Company Update |
| 2024-03-05 | Press release | Cumberland Pharmaceuticals Reports Annual 2023 Financial Results |
| 2023-11-07 | Press release | Cumberland Pharmaceuticals Reports Third Quarter 2023 Financial Results |
| 2023-08-08 | Press release | Cumberland Pharmaceuticals Reports Revenue and Earnings Growth Second Quarter 2023 |
| 2023-05-09 | Press release | Cumberland Pharmaceuticals Reports First Quarter 2023 Financial Results & Company Update |